A Kickstarter that raised $445k put the founder $150k in debt. They ran a global campaign without factoring in that shipping a $150 product to places like Saudi Arabia could cost $400, wiping out all profits and more.

A funding paradox exists where capital-efficient medical service platforms struggle to raise funds while high-risk, cash-intensive therapeutic companies secure large rounds. This is because investors understand the traditional drug development model but are unclear on how to value a medical service.

Peak Design's founder argues that Kickstarter is not a place to validate if people want a product. Instead, it should be treated as a powerful sales and marketing channel for products that are well-developed and known to solve an obvious problem. Success hinges on pre-existing product-market fit, not on discovering it.

Many groundbreaking scientific discoveries never reach patients because they fail to attract capital or secure a commercial partnership. This "translation death" highlights that business development, not just R&D, is a critical bottleneck in delivering therapies to patients.

The scientific knowledge to produce insulin is widespread. The primary barrier to creating an affordable biosimilar is not a scientific challenge but raising sufficient capital to navigate manufacturing and distribution, a problem addressed by Project Insulin's non-profit, fundraising-first model.

Sarcomatrix's CEO compares the muscular dystrophy market (90 clinics, 450 physicians) to the early, concentrated markets for Amgen (dialysis centers) and Gilead (AIDS clinics). This structure allows a startup to become a fully integrated company with a small, focused sales team, a key factor in its commercial viability.

ProKidney's significant funding from co-founder Pablo Legorreta and investor Carlos Slim was driven by their direct family experiences with kidney disease. This shows that for high-risk, long-term biotech ventures, a deep personal connection to the mission can be a more powerful motivator for investors than purely financial interest.

In the rare disease space, success hinges on deep patient community engagement. Smaller, nimbler biotechs often excel at creating these essential personal ties, giving them a significant advantage over larger pharmaceutical companies.

While passion for helping patients is a powerful motivator, founders must learn to frame their pitch around value creation for investors. This means explicitly connecting the science and clinical benefit to the commercial market, reimbursement strategy, and ultimate financial return for their limited partners.